Pharmaceutical company GlaxoSmithKline is to pay $3 billion (£1.82bn) to settle several US federal investigations into the development and marketing of some of its best-selling drugs.
One of the brands is the diabetes drug Avandia, which has been linked to heart attack risks and has been under investigation by the US Department of Justice.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.